天臣医疗(688013) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥53,710,064.08, representing a year-over-year increase of 10.30%[3] - Net profit attributable to shareholders for Q3 2021 was ¥11,484,861.94, up 17.42% compared to the same period last year[3] - The net profit attributable to shareholders for the year-to-date period was ¥36,349,565.83, showing a growth of 39.42% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2021 reached ¥152,873,142.97, a 28.6% increase from ¥118,834,772.00 in the same period of 2020[15] - Net profit for the first three quarters of 2021 was ¥36,349,565.83, representing a 39.5% increase compared to ¥26,072,007.42 in the same period of 2020[16] - The company reported a total profit of ¥39,676,722.78 for the first three quarters of 2021, up from ¥30,079,904.22 in the same period of 2020[16] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥527,157,347.01, reflecting an increase of 8.64% from the end of the previous year[4] - As of September 30, 2021, the total assets of the company amounted to RMB 527,157,347.01, an increase from RMB 485,243,095.67 as of December 31, 2020, representing a growth of approximately 8.5%[12] - The company's total current assets reached RMB 451,620,494.22, up from RMB 410,287,146.44, indicating an increase of about 10.2% year-over-year[11] - The total liabilities of the company were RMB 27,930,706.80, compared to RMB 19,350,448.82 in the previous year, reflecting a rise of approximately 44.5%[13] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 40.25% to ¥41,907,766.77[4] - Cash flow from operating activities for the first three quarters of 2021 was ¥41,907,766.77, an increase from ¥29,880,847.63 in the same period of 2020[19] - The net increase in cash and cash equivalents was -$73.85 million, compared to an increase of $246.34 million in the previous period[21] - The ending balance of cash and cash equivalents was $52.93 million, down from $126.78 million at the beginning of the period[21] Research and Development - Research and development expenses for Q3 2021 totaled ¥7,873,376.33, a significant increase of 100.64% year-over-year[4] - The proportion of R&D expenses to revenue increased to 14.66%, up 6.60 percentage points from the previous year[4] - Research and development expenses for the first three quarters of 2021 were ¥19,654,451.01, a substantial increase from ¥10,112,167.41 in the same period of 2020[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,274[9] - The company reported a basic earnings per share of ¥0.14 for Q3 2021, down 12.50% from the previous year[4] - Basic and diluted earnings per share for the third quarter of 2021 were both ¥0.45, up from ¥0.43 in the same quarter of 2020[17] Equity and Reserves - The total equity attributable to shareholders rose to RMB 499,226,640.21 from RMB 465,892,646.85, an increase of approximately 7.1%[13] - The company’s capital reserve increased to RMB 363,607,806.26 from RMB 350,736,972.86, reflecting a growth of approximately 3.7%[13] - The company’s retained earnings rose to RMB 51,824,376.74 from RMB 31,474,810.91, representing an increase of about 64.7%[13] Other Financial Metrics - The weighted average return on equity decreased to 2.35%, down 4.97 percentage points year-over-year[4] - The company's cash and cash equivalents decreased to RMB 52,927,887.55 from RMB 126,781,547.45, a decline of about 58.3%[11] - Accounts receivable increased significantly to RMB 8,934,624.49 from RMB 3,236,092.55, marking a growth of approximately 176.5%[11] - The company reported a total of 9,572,341.44 in accounts payable, which increased from RMB 3,065,594.77, indicating a growth of about 212.5%[12] - Other comprehensive income after tax for the third quarter of 2021 was ¥113,594.13, compared to a loss of ¥19,243.55 in the same quarter of 2020[17] Investment Activities - Cash inflow from investment activities in the first three quarters of 2021 included ¥854,000,000.00 from recovered investments, significantly higher than ¥14,000,000.00 in the same period of 2020[19] - The company reported a total investment cash inflow of $862.37 million, with cash outflow totaling $965.67 million[21] - Net cash flow from investment activities was -$103.30 million, compared to -$111.55 million in the previous period[21] Financing Activities - Total cash inflow from financing activities was $342.79 million, while cash outflow was $32.23 million, resulting in a net cash flow of -$16.00 million[21] Leasing Standards - The company did not apply the new leasing standards starting from 2021[21]